乳腺癌患者HER2基因表达状态及临床病理意义探讨
摘要
人类表皮生长因子受体2(HER2)定位于17号染色体q12-21,是具有酪氨酸激酶活性的跨膜生长因子受体。乳腺癌HER2基因扩增或蛋白过表达,与疾病进展和预后相关。目前临床上选用免疫组织化学(immunohistochemistry,IHC)法进行筛查,
出处
《中国实验诊断学》
北大核心
2011年第2期330-332,共3页
Chinese Journal of Laboratory Diagnosis
参考文献9
-
1Watters AD,Going JJ,Cooke TG,et a1.Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma[J].Breast Cancer Res Treat,2003,77(2):109.
-
2Risio M,Casorzo L,Redana S,et a1.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment[J].Oncol Rep,2005,13(2):305.
-
3Wong SW,Rangan AM,Bilous AM,et al.The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting[J].Pathology,1999,31(2):90.
-
4<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
-
5Press MF,Sauter G,Bernstein L,et al.Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large,prospective,randomized clinical trials[J].Clin Cancer Res,2005,11(18):6598.
-
6曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
-
7Hammock L,Lewis M,Phillips C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization[J].Hum Pathol,2003,34(10):1043.
-
8Wang S,Hossein Saboorian M,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status[J].Mod Pathol,2002,15(2):137.
-
9陈红,许建平,马小干,程应东,杨桦,孙建国,陈正堂.乳腺癌HER2基因表达阳性者17号染色体倍体性与HER2蛋白表达及临床预后因素的相关性分析[J].重庆医学,2009,38(7):803-804. 被引量:9
二级参考文献33
-
1曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
-
2曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
-
3Takehisa M, Sasa M, Bando Y, et al. Chromosomal aneusomy (ehr 1,11,17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer [J]. Anticancer Res,2007,27(2) : 1073.
-
4Mottolese M, Orlandi G, Sperduti I, et al. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage Ⅰ and Ⅱ breast cancer: Identification of an adverse prognostic profile[J]. Am J Surg Pathol,2007,31(2) :247.
-
5Wong SW, Rangan AM,Bilons AM,et al. The value of sphase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the austrifian setting[J]. Pathology, 1999,31 (2) : 90.
-
6Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/ neu amplification in breast cancer[J]. Breast J,2005,11(6) :33.
-
7Watters AD,Going J J, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma [J]. Breast Cancer Research Treatment, 2003,77 : 109.
-
8Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer:its role in HER2/neu protein expression and implication for clinical assessment of HER2/ neu status[J]. Mod Pathol, 2002,15 (2) : 137.
-
9Hammock L, Lewis M, Phillips C, et al. Strong HER2/ neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization [J]. Hum Pathol, 2003, 34 (10):1043.
-
10Yaziji H,Goldstein LC,Barry TS,et al.HER-2 testing in breast cancer using parallel tissue-based methods.JAMA,2004,291:1972-1977.
共引文献200
-
1朱萌,张宁.FISH和IHC法检测乳腺癌HER2基因一致性及其临床意义[J].宁夏医科大学学报,2013,35(9):984-986. 被引量:6
-
2董海新,张仁亚,刘启龙,赵元明,孙卓祥,郭焕,赵广章,陈涛.荧光原位杂交技术检测乳腺癌Her-2/neu基因与免疫组化法检测C-erbB2蛋白的相关性研究[J].分子诊断与治疗杂志,2009,1(2):77-82. 被引量:1
-
3陈杰.再接再厉,努力提高我国的病理诊断和研究水平[J].中华病理学杂志,2006,35(11):642-643. 被引量:4
-
4郑杰.继往开来,办好中华病理学杂志[J].中华病理学杂志,2007,36(1):1-2. 被引量:1
-
5郑杰.做好靶向病理诊断 夯实肿瘤靶向治疗的基础[J].中华病理学杂志,2007,36(7):433-434. 被引量:7
-
6沈丹华,王凤华,虞有智.显色原位杂交检测乳腺癌HER2基因扩增的应用价值[J].中华病理学杂志,2007,36(7):457-460. 被引量:3
-
7倪灿荣,白辰光.乳腺癌HER2基因扩增检测方法——显色原位杂交法的应用及优化[J].第二军医大学学报,2008,29(1):99-102. 被引量:4
-
8丁华野,薛卫成.应关注乳腺癌病理诊断中的新问题[J].中华病理学杂志,2008,37(2):75-78. 被引量:11
-
9唐源,魏兵,步宏,杨莹,陈卉娇,张璋,刘希,陈海玲,廖殿英,李俸媛.乳腺浸润性导管癌HER2免疫组化检测结果判定的重复性研究[J].临床与实验病理学杂志,2008,24(1):22-27. 被引量:10
-
10刘彤华.个性化医学时代的病理学[J].中华病理学杂志,2008,37(4):217-218. 被引量:15
-
1涂小煌.乳腺癌的化疗方案[J].中国临床医生杂志,2011,39(7):9-11. 被引量:4
-
2宋泉毅,张大昕.微RNA与肺癌及人类表皮生长因子受体突变状态的研究进展[J].医学综述,2016,22(4):703-706. 被引量:2
-
3杨顺娥,李迅.雌激素受体β和人类表皮生长因子受体2在乳腺癌中的表达及其临床意义[J].中华肿瘤杂志,2007,29(10):767-768. 被引量:6
-
4周桂台.三阴乳腺癌的临床特点及预后分析[J].中国当代医药,2010,17(31):157-157.
-
5舒文斌,曹家庆.HER-2在胃癌研究中的新进展[J].生命科学,2013,25(3):324-328. 被引量:3
-
6王春燕,汤丽娜,祁伟祥,张剑军,郑水儿,姚阳,林峰.HER-2过表达与骨肉瘤预后关系的Meta分析[J].山东医药,2015,55(8):70-72.
-
7任泽华,张一清,李金峰.乳腺浸润性小叶癌与浸润性导管癌比较分析[J].中国药物与临床,2012,12(8):1075-1077. 被引量:5
-
8李森,李治国,成龙,薛英威.H er -2阳性胃癌靶向治疗的研究进展[J].实用肿瘤学杂志,2015,29(2):188-192. 被引量:7
-
9王传省,张芳.三阴性乳腺癌96例临床特征与预后分析[J].肿瘤研究与临床,2013,25(5):350-352. 被引量:10
-
10乔建兵,陈文萍.酪氨酸激酶抑制剂耐药机制及其治疗策略[J].中国肺癌杂志,2011,14(10):806-810. 被引量:4